(Q41640583)

5 October 2017

1 reference

title

Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants (English)

1 reference

5 October 2017

C M Masimirembwa

1

1 reference

5 October 2017

J A Hasler

series ordinal

2

1 reference

5 October 2017

publication date

1 January 1997

1 reference

5 October 2017

published in

Brain Research Bulletin

1 reference

5 October 2017

volume

44

1 reference

5 October 2017

issue

5

1 reference

5 October 2017

page(s)

561-571

1 reference

The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Nomenclature for human CYP2D6 alleles.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Diazepam effects and kinetics in Caucasians and Orientals

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Biochemistry and molecular biology of the human CYP2C subfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Differences in diazepam pharmacokinetics in Chinese and white Caucasians--relation to body lipid stores.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Differences in drug metabolism polymorphism between Orientals and Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

A study of the debrisoquine hydroxylation polymorphism in a Nigerian population

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Newer antidepressants and the cytochrome P450 system

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Oxidative polymorphism of dextromethorphan in a Burundi population.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Absence of Polymorphism of Sparteine Oxidation in the South African Venda

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Debrisoquine oxidation phenotype during neuroleptic monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Genetic polymorphism of S-mephenytoin hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Ethnic differences in drug disposition and responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FS0361-9230%2897%2900307-9

7 January 2021

10.1016/S0361-9230(97)00307-9

Identifiers

DOI

1 reference

5 October 2017

1 reference